CPT1C

Across TCGA pan-cancer cohorts, CPT1C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPT1C data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CPT1C Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CPT1C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, KIRP, and PCPG are the cancer types where CPT1C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.612	.001	32	view →
KIRP	OS	Median	All	0.209	0.908	<.001	30	view →
PCPG	OS	Median	All	0.142	0.963	<.001	12	view →
LIHC	OS	Median	All	0.452	0.785	.011	12	view →
SKCM	OS	Median	IV	0.133	0.621	.019	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPT1C–UCEC (DFS)

Open the UCEC breakdown →